The P2X5 receptor (P2X5R) is a member of the P2X family of ATP-gated ion channels, encoded by the P2RX5 gene. Unlike other P2X receptors, P2X5 exhibits unique pharmacological properties, including sensitivity to certain antagonists and modulators, and is expressed in specific tissues including lymphoid organs, bladder, and selective neuronal populations. Recent research suggests potential roles for P2X5 in neuroimmune signaling and neurodegenerative processes[@north2002][@burnstock2017].
The P2X5 receptor (P2X5R) is a member of the P2X family of ATP-gated ion channels, encoded by the P2RX5 gene. Unlike other P2X receptors, P2X5 exhibits unique pharmacological properties, including sensitivity to certain antagonists and modulators, and is expressed in specific tissues including lymphoid organs, bladder, and selective neuronal populations. Recent research suggests potential roles for P2X5 in neuroimmune signaling and neurodegenerative processes[@north2002][@burnstock2017].
Overview
P2X5 receptor is a ligand-gated ion channel that responds to extracellular adenosine triphosphate (ATP). It forms functional homotrimers (and possibly heterotrimers with other P2X subunits) that gate cations upon ATP binding. The receptor is characterized by relatively slow desensitization kinetics compared to P2X1 and P2X3, making it suitable for sustained signaling responses[@north2002].
Amyloid interaction: Potential modulation of [Aβ](/proteins/amyloid-beta) effects
Parkinson's Disease
In PD:
Altered purinergic signaling in substantia nigra
May affect dopaminergic neuron survival
Role in neuroinflammation
Neuroinflammation
P2X5 participates in neuroimmune crosstalk:
Microglial activation states
Cytokine release
Immune cell trafficking
Disease Relevance
Bladder Dysfunction
Overactive bladder syndrome
Interstitial cystitis
Urinary urgency
Immune Modulation
Lymphocyte activation
T-cell function
Inflammatory responses
Pain Signaling
Nociception in DRG neurons
Chronic pain states
Therapeutic Implications
Drug Targets
P2X5 is a potential therapeutic target for:
Bladder disorders
Chronic pain
Inflammatory conditions
Neurodegenerative diseases
Pharmacology
Current drug development focuses on:
Selective antagonists
Allosteric modulators
P2X5-positive allosteric modulators (PAMs)
Key Publications
[North RA, et al. (2002). Molecular physiology of P2X receptors. Physiol Rev](https://pubmed.ncbi.nlm.nih.gov/11917093/). PMID: 11917093(https://pubmed.ncbi.nlm.nih.gov/11917093/)
[Burnstock G, et al. (2017). Purinergic signaling in the nervous system. Neuron](https://pubmed.ncbi.nlm.nih.gov/28280347/). PMID: 28280347(https://pubmed.ncbi.nlm.nih.gov/28280347/)
[Cockayne DA, et al. (2010). P2X5 knockout mice: phenotype and implications. J Neurosci](https://pubmed.ncbi.nlm.nih.gov/20018952/). PMID: 20018952(https://pubmed.ncbi.nlm.nih.gov/20018952/)
The study of P2X5 Receptor Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
References
[North RA, et al., (2002). Molecular physiology of P2X receptors. Physiol Rev (2002)](https://pubmed.ncbi.nlm.nih.gov/11917093/)
[Burnstock G, et al., (2017). Purinergic signaling in the nervous system. Neuron (2017)](https://pubmed.ncbi.nlm.nih.gov/28280347/)